Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Biosimilars Meeting Seeks Input On Product Naming, Foreign Data And Exclusivity

This article was originally published in The Pink Sheet Daily

Executive Summary

Two-day public hearing in November will cover nearly all aspects of the new pathway except the patent challenge mechanism.

You may also be interested in...



Biosimilars: FDA's Meeting Notice Upgrades Safety To "Paramount"

Updated outline of November meeting discussion points includes several tweaks to the pharmacovigilance section.

Biosimilars: FDA's Meeting Notice Upgrades Safety To "Paramount"

Updated outline of November meeting discussion points includes several tweaks to the pharmacovigilance section.

Biosimilar Road Bump: Teva Filgrastim's Complete Response Shows Even Full BLAs Can Stumble

FDA issued a complete response letter requesting "several items" from Teva to finish review of its biological license application.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071201

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel